Table 1.
Characteristics of the patients in the RATE and TE groups.
| RATE (N = 51) | TE (N = 70) | P | |
|---|---|---|---|
| Age, years, median (range) | 65 (44–80) | 67 (41–85) | 0.212 |
| Sex, n (%) | |||
| Male | 45 (88%) | 60 (86%) | 0.790 |
| Female | 6 (12%) | 10 (14%) | |
| Tumor location, n (%) | |||
| Upper | 8 (16%) | 11 (16%) | 0.839 |
| Middle | 20 (39%) | 30 (43%) | |
| Lower | 16 (31%) | 23 (33%) | |
| Esophagogastric junction | 7 (14%) | 6 ( 9%) | |
| cT, n(%) | |||
| T1 | 18 (35%) | 23 (37%) | 0.494 |
| T2 | 9 (18%) | 6 (9%) | |
| T3 | 23 (45%) | 37 (53%) | |
| T4 | 1 ( 2%) | 1 (1%) | |
| cN, n (%) | |||
| 0 | 23 (45%) | 34 (49%) | 0.717 |
| 1–2 | 28 (55%) | 36 (51%) | |
| Number of involved nodes, median (range) | 1 ( 0–6) | 1 ( 0–4) | 0.560 |
| cStage, n (%) | |||
| IA | 13 (25%) | 23 (33%) | 0.448 |
| IB | 5 (10%) | 3 ( 4%) | |
| IIA | 5 (10%) | 8 (11%) | |
| IIB | 9 (18%) | 4 ( 6%) | |
| IIIA | 9 (18%) | 18 (26%) | |
| IIIB | 6 (12%) | 9 (13%) | |
| IIIC | 1 ( 2%) | 1 ( 1%) | |
| IV | 3 ( 6%) | 4 ( 6%) | |
| Histological type of cancer | 0.200 | ||
| Squamous cell carcinoma | 43 (84%) | 64 (91%) | |
| Adenocarcinoma | 6 (12%) | 6 (9%) | |
| Other | 2 (4%) | 0 (0%) | |
| Neoadjuvant therapy, n (%) | |||
| Chemoradiotherapy | 27 (53%) | 31 (44%) | 0.311 |
| Chemotherapy | 2 (4%) | 7 (10%) | |
| Endoscopic resection | 1 (2%) | 5 (7%) | |
| None | 21 (41%) | 27 (39%) | |